HealthEquity's HSA Enrollment Growth Will Determine If the Thesis Still Works

HealthEquity reports earnings after the close on May 28, 2026, with analysts expecting $0.94 per share — a significant acceleration from prior quarters. The central question is whether the health savings account administrator can sustain its impressive streak of double-digit earnings beats while navigating a maturing HSA market and evolving regulatory landscape.

Part 1: Earnings Preview

HealthEquity (HQY) is a leading health savings account (HSA) administrator and benefits platform provider, serving employers and individuals with tax-advantaged healthcare accounts. The company generates revenue through custodial fees, interchange income, and investment advisory services tied to HSA balances.

HealthEquity is scheduled to report fiscal Q1 2027 results after the close on May 28, 2026. The consensus estimate stands at $0.94 per share from 6 analysts, with estimates ranging from $0.91 to $0.96. The company most recently reported $0.78 per share for the January 2026 quarter. Compared to the same quarter last year when HQY earned $0.84, the current estimate implies +11.90% year-over-year growth — a notable reacceleration after several quarters of more modest expansion.

Three key themes define this earnings story:

HSA Account Growth and Enrollment Trends: Investors will scrutinize net new account additions and member engagement metrics. The company's ability to win large employer contracts and retain existing customers remains critical to long-term revenue visibility, particularly as the HSA market matures and competition intensifies from both traditional benefits administrators and fintech entrants.

Custodial Revenue and Interest Rate Sensitivity: With a significant portion of revenue tied to interest earned on HSA cash balances, the interest rate environment directly impacts profitability. Analysts are watching whether HealthEquity can maintain or expand net interest margins while balancing competitive pressures to pass rate increases through to account holders.

Operating Leverage and Margin Expansion: After investing heavily in technology infrastructure and integration of past acquisitions, the market is focused on whether HQY can demonstrate meaningful operating leverage. Analysts expect the company to show progress on cost discipline while maintaining the service quality that differentiates its platform.

Leading analysts remain constructive heading into the print. The consensus has been revised upward from $0.84 to $0.94 over recent months, reflecting growing confidence in the company's execution. Analysts point to strong open enrollment season results and improving cross-sell metrics as tailwinds, though some caution that valuation has become more demanding following the stock's recent run.

Part 2: Historical Earnings Performance

HealthEquity has established a remarkably consistent pattern of exceeding expectations, beating consensus estimates in each of the past four quarters. The company delivered a +35.48% surprise in April 2025 with $0.84 versus $0.62 expected, followed by a +22.67% beat in July 2025 ($0.92 vs. $0.75), a +15.49% beat in October 2025 ($0.82 vs. $0.71), and most recently an +11.43% beat in January 2026 ($0.78 vs. $0.70).

The magnitude of beats has been substantial but shows a moderating trend — from the extraordinary 35% upside surprise a year ago to the still-impressive but more modest 11% beat last quarter. This pattern suggests either that analysts are becoming more accurate in modeling the business, or that the company's outperformance is normalizing as easier comparisons fade. The sequential decline in absolute EPS from $0.92 in July to $0.78 in January reflects typical seasonality in the HSA business, where custodial revenue and account activity vary throughout the fiscal year.

Investors should note that while the beat streak is impressive, the current $0.94 consensus already embeds expectations for continued outperformance. The estimate has risen 12% from $0.84 just months ago, indicating analysts have adjusted their models upward to reflect the company's execution strength. This sets a higher bar for another meaningful surprise.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

HealthEquity reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 represents the first full session of market reaction to actual earnings.

The historical data reveals substantial post-earnings volatility, with Day +1 moves averaging 6.27% in absolute terms and intraday ranges averaging 7.81%. The most dramatic reaction came in March 2025, when the stock plunged 17.07% the day after reporting despite beating estimates — suggesting guidance or commentary disappointed investors even as the quarter exceeded expectations. More recently, the stock has shown positive momentum following earnings, with gains of 8.96% (June 2025) and 7.53% (September 2025) in the Day +1 session.

The Day 0 moves are relatively muted at 0.76% on average, which is typical for after-hours reporters where the market hasn't yet digested results. Investors should prepare for meaningful volatility in the May 29 session, with historical precedent suggesting a move in the 6-8% range is well within normal bounds. The direction of that move will likely hinge not just on the EPS beat, but on guidance commentary around account growth, margin trajectory, and full-year outlook.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.60% expected move through the June 18 expiration, which is notably higher than the historical average Day +1 move of 6.27%. This suggests options traders are anticipating above-average volatility for this particular release, possibly reflecting uncertainty around guidance or heightened sensitivity to the company's growth outlook given the stock's recent momentum.

Part 3: What Analysts Are Saying

Analyst sentiment on HealthEquity is decidedly bullish, with an average recommendation of 4.59 out of 5.00 — firmly in Strong Buy territory. The consensus breaks down to 14 Strong Buys, 1 Moderate Buy, 1 Hold, and 1 Strong Sell among 17 analysts covering the stock. This overwhelmingly positive stance reflects confidence in the company's competitive positioning and long-term growth trajectory in the expanding HSA market.

The average price target of $112.88 implies 30% upside from the current price of $86.56, with the high target of $128.00 suggesting some analysts see potential for even greater appreciation. The wide range between the low target of $86.00 and the high of $128.00 reflects differing views on valuation multiples and growth sustainability, though the lone bearish analyst appears to be an outlier.

Sentiment has remained unchanged over the past month, indicating analysts are holding steady in their conviction rather than chasing the stock higher or growing more cautious. The stability in ratings suggests the analyst community is comfortable with current valuation levels and believes the growth story remains intact heading into this earnings report.

Part 4: Technical Picture

HealthEquity's technical setup heading into earnings shows improving momentum after a period of weakness. The Barchart Technical Opinion has shifted dramatically from a 32% Sell signal one week ago to an 8% Buy signal currently, and has recovered substantially from the 48% Sell signal registered one month ago. This rapid reversal suggests near-term buying pressure has emerged, though the "Minimum" strength rating indicates the signal lacks conviction.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive but remains tentative
• Medium-term (Hold): Neutral reading suggests the intermediate trend is in consolidation mode
• Long-term (50% Sell): Moderate sell signal reflects underlying weakness in the longer-term trend structure

Trend Characteristics: The "Weakest" direction combined with "Minimum" strength suggests the trend environment remains fragile and lacks clear directional conviction heading into earnings.

The stock is trading at $86.56, positioned above its 10-day ($85.03), 20-day ($83.76), 50-day ($82.89), and 100-day ($82.51) moving averages, but remains below both its 5-day ($87.18) and critical 200-day ($88.45) moving average. This configuration shows short-term strength building as the stock has climbed above multiple intermediate support levels, but the failure to reclaim the 200-day average suggests longer-term resistance remains overhead. The technical setup is cautiously supportive — momentum has improved and the stock has established a base above key moving averages, but the lack of a decisive breakout above the 200-day and the conflicting timeframe signals suggest traders should prepare for volatility. A strong earnings beat could provide the catalyst to clear overhead resistance, while any disappointment could quickly reverse recent gains given the tentative nature of the current trend.